Aurobindo Pharma gets NDA from USFDA

HYDERABAD: Aurobindo Pharma on Thursday announced the receipt of the first New Drug Approval (NDA) from the USFDA for Lamivudine 150 mg/Zidovudine 300 mg, fixed dose tablets co-packed with Efavirenz 600 mg tablets. The NDA provided the drugs for treatment of HIV-1 infection and there is no previous version of the co-packaged product approved by USFDA. This is Aurobindo Pharma's eleventh approval for the anti-retroviral segment and helps retain its position as a strong player in the segment, says a company release.